Compass Therapeutics, Inc. (CMPX)
(Delayed Data from NSDQ)
$2.91 USD
-0.02 (-0.68%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $2.92 +0.01 (0.34%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CMPX 2.91 -0.02(-0.68%)
Will CMPX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CMPX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CMPX
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: What Does It Mean for the Stock?
Compass Therapeutics Stock Skyrockets 108% in a Month: Here's Why
CMPX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Compass Therapeutics, Inc. (CMPX) Stock Outpacing Its Medical Peers This Year?
Down -23.46% in 4 Weeks, Here's Why You Should You Buy the Dip in Compass Therapeutics, Inc. (CMPX)
What Makes Compass Therapeutics, Inc. (CMPX) a New Buy Stock
Other News for CMPX
Compass Therapeutics (CMPX) Receives Outperform Rating from Raymond James | CMPX Stock News
Compass Therapeutics resumed with an Outperform at Raymond James
Compass Therapeutics Completes Phase 2 Study on CTX-009 for Metastatic Colorectal Cancer
Compass Therapeutics (CMPX) Receives a Buy from Piper Sandler
Compass Therapeutics management to meet virtually with Piper Sandler